SA.41471(2015/X) Purpose_public_aid: Article 25 of Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty (OJ Urz. EU L 187/1 of 26.06.2014).The aim of the project is to develop a drug candidate based on the technology of induced protein degradation, which by eliminating cancer stem cells (CCC) will help inhibit the development of Hepatocellular carcinoma (HCC). HCC is the most common type of primary liver cancer. In the world, HCC occupies 5th place in cancer incidence and is the third cause of cancer deaths. The high mortality rate of HCC patients is largely associated with their late diagnosis and limited treatment methods. At present, surgical intervention (liver resection or transplant) is the only method that gives a chance to completely cure patients, but this approach can be applied in less than 30 % of cases. In other cases, topical therapy (thermoablations), systemic therapy (sorafenib) or radiotherapy is used. This medicine is currently a first-line medicine available to patients with advanced HCC. It allows the average survival time to be extended by about 3 months, but this is often accompanied by side effects. Studies indicate that the activation of the selected molecular target is a key factor in the development of this type of cancer. Particularly high expression of this protein is observed in the population of the most aggressive HCC cells, which have characteristics of cancer stem cells, such as high invasive potential or drug resistance. The project will develop a small-molecular compound that will allow selective degradation of the molecular target necessary for the functioning of CSC cells, thereby increasing the effectiveness of the currently available therapies. [...]